- Home
- LXEH vs APRE Comparison
LXEH vs APRE Comparison
Compare LXEH & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LXEH | APRE |
|---|---|---|
| Founded | 2001 | 2006 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1M | 6.9M |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | LXEH | APRE |
|---|---|---|
| Price | $0.23 | $0.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | ★ 189.8K | 68.9K |
| Earning Date | 12-30-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,585,942.00 | $488,239.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.22 | $0.90 |
| 52 Week High | $50.08 | $5.00 |
Technical Indicators
Market Signals| Indicator | LXEH | APRE |
|---|---|---|
| Relative Strength Index (RSI) | 26.63 | 34.26 |
| Support Level | $0.27 | $0.91 |
| Resistance Level | $0.31 | $1.14 |
| Average True Range (ATR) | 0.02 | 0.08 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 14.95 | 16.67 |
Price Performance
Historical ComparisonAbout LXEH Lixiang Education Holding Co. Ltd.
Lixiang Education Holding Co Ltd is a private primary and secondary education service provider in Lishui City, Zhejiang Province. Its private education services primarily include primary and middle school education from grade 1 to grade 9. The company also offers high school education services at its High School Divisions.
About APRE Aprea Therapeutics Inc.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.